Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo.
Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo.
复制标题
DOI：
10.1038/srep22390
复制
发表时间：
2016-03-07
影响因子：
4.6
通讯作者：
Yang XD
中科院分区：
文献类型：
--
作者：
Meng J;Guo F;Xu H;Liang W;Wang C;Yang XD
耐多药（MDR）是癌症治疗的主要障碍。治疗耐多药的一个很有前途的策略是在单一纳米载体中联合向肿瘤细胞递送联合抗癌药物。在这里，白藜芦醇（Res）首次与紫杉醇（PTX）在聚乙二醇化脂质体中共包被，以构建一种载体递送形式的联合治疗耐药肿瘤。复合脂质体的平均直径为50 nm，包封效率在50%以上。研究表明，复合脂质体在体外可对耐药MCF-7/Adr肿瘤细胞产生强大的细胞毒性，提高药物在体内的生物利用度和肿瘤保留率。此外，复合脂质体全身治疗可有效抑制小鼠耐药肿瘤（p < 0.01），而毒性无明显增加。这些结果表明，在纳米载体中共同递送Res和细胞毒性药物可能会改善耐药肿瘤的治疗。
Multidrug resistance (MDR) is a major impediment to cancer treatment. A promising strategy for treating MDR is the joint delivery of combined anticancer agents to tumor cells in a single nanocarrier. Here, for the first time, Resveratrol (Res) was co-encapsulated with paclitaxel (PTX) in a PEGylated liposome to construct a carrier-delivered form of combination therapy for drug-resistant tumors. The composite liposome had an average diameter of 50 nm with encapsulated efficiencies of above 50%. The studies demonstrated that the composite liposome could generate potent cytotoxicity against the drug-resistant MCF-7/Adr tumor cells in vitro and enhance the bioavailability and the tumor-retention of the drugs in vivo. Moreover, systemic therapy with the composite liposome effectively inhibited drug-resistant tumor in mice (p < 0.01), without any notable increase in the toxicity. These results suggested that the co-delivery of Res and a cytotoxic agent in a nanocarrier may potentially improve the treatment of drug-resistant tumors.